<DOC>
	<DOCNO>NCT02898805</DOCNO>
	<brief_summary>The study design compare effect two combination nutraceuticals : Armolipid Plus® LopiGLIK® ( Akademy Pharma ) , new supplement , addition Berberine Red Rice , contain Morus Alba 's extract . The study analyze impact 16 week treatment one combination , accord randomized scheme , metabolic parameter dyslipidemic subject require tolerate statin therapy . In particular , assess ability two combination reduce level total LDL cholesterol , HbA1C , glicaemia insulin increase HDL cholesterol .</brief_summary>
	<brief_title>Effects LopiGLIK® Cardiovascular Risk</brief_title>
	<detailed_description>The experimental design involve construction multi-center , control , randomize , single-blind , versus Armolipid Plus® . Patients mild hypercholesterolemia , sex age 18 75 year , recruit , begin study next 2 week , 30 Cv specialist and/or GPs ( 25 patient ) . The subject enrol 50/50 % male/female ratio ± 10 % comparable age , order obtain proper comparison group similar demographic characteristic statistically different . The subject , select basis inclusion exclusion criterion , divide two group , subject centralized randomization `` Diagnosis Treatment hypertension Center '' receive one two different treatment , tablet/day new nutraceutical LopiGLIK® ( Akademy Pharma ) contain Morus Alba , immediately meal , vs. tablet/day Armolipid Plus , always immediately meal . During first two week group follow prescribe diet assume placebo . At end , blood test ( traditional metabolic parameter , blood glucose , HbA1C , fast insulin , transaminase level , CPK ) endothelial function assesed . During next 16 week group assume LopiGLIK® ( Akademy Pharma ) contain Morus Alba , assume Armolipid Plus everyone continue follow prescribe diet . At end period blood test repeat . Tablets Armolipid Plus , LopiGLIK® placebo provide Akademy Pharma free charge</detailed_description>
	<criteria>Total Cholesterol &lt; 300 mg/dL Total Cholesterol &gt; 200 mg/dL Cardiovascular Risk &lt; 20 % Pregnancy Documented intolerance one 'components LOPIGLIK / Armolipid PLUS Previous cardiovascular event Familiar severe dyslipidemia Familiar high cardiovascular risk Hepatic muscular disorder Subjects receive lipidlowering drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>